Liver cancer: Lenvatinib non-inferior to sorafenib for hepatocellular carcinoma
- PMID: 29487423
- DOI: 10.1038/nrgastro.2018.20
Liver cancer: Lenvatinib non-inferior to sorafenib for hepatocellular carcinoma
Comment on
-
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1. Lancet. 2018. PMID: 29433850 Clinical Trial.
References
-
- Lancet. 2018 Feb 9;:null - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical